For ten years kidney transplantation has been used as a method for treating patients with irreversible kidney failure. During this time the procedure has become safer for the patient but there has not been a corresponding improvement in the proportion of kidneys that survive. Transplantation of organs other than kidney is being attempted on a more limited scale. Liver transplantation is a formidable operation and understandably its practice has become restricted to a few centres (notably Denver and Cambridge) where skill and expertise can be properly concentrated. Heart transplantation is technically easier, and there seem to be fewer serious complications afterwards. By far the best results have emanated from Stanford where Shumway has been performing heart transplants at the rate of one a month. His results (50 % of patients surviving one year) can be compared favourably with the survival of cadaver kidney transplants.
About 40 persons per million of the population develop kidney failure each year. Often these patients are young and a small proportion are children. Hemodialysis can keep these people alive and 60 % of patients under treatment in this country are on home dialysis. None the less it is an expensive undertaking and sooner or later these patients will require a kidney transplant, if only to escape from the boredom of chronic himodialysis. Kidneys can be obtained from a willing relative or from someone who has just died. There is no doubt that a well-matched kidney from a brother or sister offers the best chances of survival and 80 % of such kidneys can be expected to be functioning a year after transplantation. However, in the United Kingdom live donor transplantation has never been popular and the majority of kidneys transplanted have come from totally unrelated people who have died. Considerable effort has been expended in trying to improve the quality of cadaver kidneys. When a person dies suddenly and unexpectedly there may be a delay of an hour or more while permission to remove kidneys is obtained from relatives and other arrangements have been put in hand for removal of the kidneys. During this period the kidneys can become severely damaged and a proportion will never function again after transplantation. Nowadays kidneys are taken mostly from patients who have suffered severe brain damage and who have been maintained on ventilators. If the patient fails to recover, then ventilation is usually abandoned and the transplant surgeons are duly notified so that they can be on hand to remove the kidneys as soon as the heart has stopped. In many countries. when kidneys are removed under these circumstances the ventilator is switched off after the kidneys have been removed rather than before. In this way the kidneys suffer the least amount of ischmmic damage. This concept is gaining gradual acceptance in the United Kingdom and as a result the number of kidneys with 'primary nonfunction' should diminish considerably.
Once the kidneys have been removed they will remain in good condition for 12-14 hours provided they are kept cool. This is usually achieved by placing them in plastic bags and surrounding them with ice. Preservation is improved if the blood is first washed out of the kidney by perfusing a solution through the renal artery. Various solutions have been advocated but the most commonly employed is Collins' C3 solution 7 527 which resembles intracellular fluid in ionic composition and strength. Twelve hours is usually quite sufficient time for transporting the kidney to the most suitable recipient and for making arrangements for the transplant operation. Occasionally longer periods of preservation are required and this can be achieved by perfusing the kidney on a special preservation machine. The machine perfuses the kidneys with a cold plasma-based fluid which is kept oxygenated and at the correct pH. During perfusion the viability of the kidney can be assessed in some measure, allowing severely damaged ones to be identified and discarded. Whether perfused kidneys function longer is a matter for debate. In an Australian series of cadaver transplants a greater percentage of perfused kidneys survived one year when compared with those that had merely been cooled (Sheil et al. 1975) . However, in a large series of transplants carried out in California this was not confirmed; in fact, in this study the perfused kidneys functioned for a considerably shorter time (Fine et al. 1975 ).
To prevent rejection of the kidney immunosuppressive drugs are given indefinitely. Initially prednisolone is administered in a high dose, but over ensuing weeks this can usually be reduced. Antilymphocyte globulin (ALG) has been shown to have remarkable immunosuppressive properties in animals, and as a result it has been used widely in man. However, there have been very few controlled clinical trials using this agent and even now it is not clear whether it is effective. In Australia a controlled trial demonstrated a beneficial effect of ALG (Sheil et al. 1971 ) but similar trials conducted in-the United States and elsewhere have failed to confirm this. A doubleblind controlled clinical trial is under way in the United Kingdom and its results are awaited with interest. Other drugs have been advocated as being helpful in preventing or delaying rejection. Anticoagulants came into vogue a few years ago but controlled studies reveal no benefit (Barnes et al. 1974) . The management of rejection episodes has altered. High doses of orally administered steroids can produce severe complications and it is now clear that rejection can be reversed as successfully by two or three intravenous 1 gram doses of methylprednisolone. The mortality associated with this treatment is much less than that which accompanies the use of high oral doses of prednisolone (Clarke & Salaman 1975) . The effect of previous blood transfusions on transplant survival has come under discussion. Previously it was thought that transfusing dialysis patients was unwise since a proportion would develop antibodies which could then react with a subsequent transplant. However, Terasaki and his co-workers have shown that a proportion of patients will not develop antibodies however many units of blood they receive (Opelz et al. 1972 ). These patients have been termed 'poor responders' and on receiving a kidney transplant appear to experience fewer rejection problems. In these prople blood transfusions may act in some beneficial way by generating enhancing antibodies. Certainly of the 'poor responder' patients those who have been deliberately deprived of blood transfusions do much less well after transplantation (Opelz & Terasaki 1974) .
Although serving a clinical need, kidney transplantation is not as successful as desired. Just under half the cadaver kidneys are lost, chiefly from rejection, within the first year after transplantation. Close tissue matching between donor and recipient has been the policy for a number of years in most centres in the UK, but what influence tissue matching has on kidney graft survival is still not clear. My personal belief is that the results of transplantation will improve only as a result of better immunosuppressive treatment.
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Specific Suppression of Organ Graft Rejection
The scope of transplantation as a therapeutic procedure and its utility even in well-established areas such as renal failure are limited by the toxicity and inadequate potency of the immunosuppressive agents currently in use. These agents are largely nonspecific in their immunological effects and moreover they produce undesired side-effects outside the immune system. Specific immunosuppression directs itself solely at the lymphocyte clones responsible for the rejection of the particular graft the patient receives, and it 'Wellcome Senior Research Fellow in Clinical Science
